Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics...
February 13 2017 - 7:00AM
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has
received a task order from the Biomedical Advanced Research and
Development Authority (BARDA) valued at up to $30.5 million to
develop monoclonal antibody therapeutics for viral hemorrhagic
fever. This task order will utilize the company’s Center for
Innovation in Advanced Development and Manufacturing (CIADM)
facility located in Baltimore, Maryland. Using monoclonal
antibodies from Mapp Biopharmaceutical Inc., the company will
conduct technology transfer of process materials and information,
perform process and analytical method development, execute
small-scale production runs, and perform cGMP cell banking leading
to cGMP manufacture of bulk drug substance. The task order consists
of a 36-month period of performance with a base task order valued
at $7.4 million and options that, if executed, will bring the total
task order value over three years to up to $30.5 million.
“Protecting and enhancing life is at the core of Emergent’s
mission, and one of the ways by which we are able to fulfill this
mission is in partnership with BARDA as it addresses emerging
public health threats,” said Adam Havey, executive vice president
and president, biodefense division of Emergent BioSolutions.
“Emergent’s CIADM is a great example of a public-private
partnership that works towards a shared goal. We look forward to
successfully executing this task order in collaboration with all
parties involved.”
This is the fourth BARDA Task Order awarded to Emergent under
the CIADM program. Since its inception in 2012, Emergent’s CIADM
facility has been utilized to respond to public health emergencies
including Ebola and Zika.
This Task Order Number HHSO10033004T under contract
HHSO100201200004I is funded by BARDA, within the Office of the
Assistant Secretary for Preparedness and Response in HHS.
About Emergent BioSolutionsEmergent
BioSolutions Inc. is a global life sciences company seeking to
protect and enhance life by focusing on providing specialty
products for civilian and military populations that address
accidental, intentional, and naturally emerging public health
threats. Through our work, we envision protecting and enhancing 50
million lives with our products by 2025. Additional information
about the company may be found at emergentbiosolutions.com. Follow
us @emergentbiosolu.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including statements
regarding the exercise of options under the task order, are
forward-looking statements. These forward-looking statements are
based on our current intentions, beliefs and expectations regarding
future events. We cannot guarantee that any forward-looking
statement will be accurate. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could differ materially
from our expectations. Investors are, therefore, cautioned not to
place undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to
update any forward-looking statement to reflect new information,
events or circumstances. There are a number of important factors
that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including
the availability of funding and BARDA’s exercise of options under
the task order; the success of the planned development programs;
the timing of and ability to obtain and maintain regulatory
approvals for the product candidates; and commercialization,
marketing and manufacturing capabilities. The foregoing sets forth
many, but not all, of the factors that could cause actual results
to differ from our expectations in any forward-looking statement.
Investors should consider this cautionary statement, as well as the
risk factors identified in our periodic reports filed with the SEC,
when evaluating our forward-looking statements.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
Media Contact:
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3281
SchmittT@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Sep 2023 to Sep 2024